Why BeyondSpring Inc. (BYSI) stock soared on Friday?

0
436

BeyondSpring Inc. (BYSI) shares surged 12.61% in after-hours on Friday, November 26, 2021, and closed the weekly trading at $16.16. Even in the regular trading session of Friday, BYSI’s stock gained 8.06%. BYSI shares have risen 31.77% over the last 12 months, and they have moved up 7.73% in the past week. Over the past three months, the stock has lost 50.17%, while over the past six months, it has gained 38.38%.

Let’s see is there any recent news behind its good performance on Friday?


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


>> 7 Top Picks for the Post-Pandemic Economy << 

BYSI participation in the upcoming event

BeyondSpring (BYSI) management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, which is to be held on November 30-December 2, 2021.

Read More

BYSI participation in the recent event

BeyondSpring (BYSI) recently participated at Jefferies London Healthcare Conference which was held on November 18-19, 2021. The company had one-on-one investor meetings during the event.

BYSI new appointment

On November 10, 2021, BeyondSpring Pharmaceuticals (BYSI), appointed Mark Santos, RPh, to its Board of Directors. Mr. Santos has over 30 years of executive experience across the healthcare and pharmaceutical industries, currently serving as the Senior Vice President of Pharma Strategy & Contracting at OneOncology. He was President of ION Solutions, the leading GPO in the U.S., from 2011 to 2018.

BYSI update about plinabulin

On October 21, 2021, BeyondSpring (BYSI) announced that the first patient has been treated in an investigator-initiated, open-label Phase 2 study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3rd line recurrent small-cell lung cancer (SCLC) who failed checkpoint inhibitors and platinum-based chemotherapy. This Phase 2 study, to be conducted through the Big Ten Cancer Research Consortium in 7 U.S. clinical centres, comes after the successful completion of Phase 1 dose-escalation study portion of this Phase 1/2 study.

Plinabulin ability to enhance the anti-cancer effects and reduce the Grade 3/4 IR-AEs of PD-1 and CTLA-4 inhibitors makes it an ideal addition to these checkpoint inhibitors for establishing the concept of a ‘chemo free therapeutic strategy for cancer patients.

>> 7 Top Picks for the Post-Pandemic Economy << 

Conclusion

Well, as of this writing, there is no recent news which could be linked with its good performance on Friday. We hope that it will continue its momentum on Monday as well.

LEAVE A REPLY

Please enter your comment!
Please enter your name here